1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: Identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile

Journal of Medicinal Chemistry

Volumn 49, Issue 24, 2006, Pages 7247-7251

  Fancelli, Daniele ^a,b   Moll, Jürgen ^a   Varasi, Mario ^a,b   Bravo, Rodrigo ^a   Artico, Roberta ^a,c   Berta, Daniela ^a   Bindi, Simona ^a   Cameron, Alexander ^a   Candiani, Ilaria ^a   Cappella, Paolo ^a   Carpinelli, Patrizia ^a   Croci, Walter ^a   Forte, Barbara ^a   Giorgini, Maria Laura ^a   Klapwijk, Jan ^a,d   Marsiglio, Aurelio ^a   Pesenti, Enrico ^a   Rocchetti, Maurizio ^a   Roletto, Fulvia ^a   Severino, Dino ^a   Soncini, Chiara ^a,e   Storici, Paola ^a   Tonani, Roberto ^a   Zugnoni, Paola ^a   Vianello, Paola ^a   more..

^a NERVIANO MEDICAL SCIENCES   (Italy)

^b Congenia ^*  (Italy)

^c Italfarmaco SpA   (Italy)

^d GLAXOSMITHKLINE   (United Kingdom)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,6 TETRAHYDROPYRROLO[3,4 C]PYRAZOLE DERIVATIVE; AURORA A KINASE; AURORA B KINASE; AURORA KINASE INHIBITOR; PHA 680632; PHOSPHOTRANSFERASE INHIBITOR; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN HL 60; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TUMOR; TUMOR MODEL; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; MALE; MICE; MODELS, MOLECULAR; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; PYRROLES; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33845367377     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060897w     Document Type: Article

References (20)

1. Matthews, N.; Visintin, C.; Hartzoulakis, B.; Jarvis, A.; Selwood, D. L. Aurora A and B kinases as targets for cancer: will they be selective for tumors? Expert Rev. Anticancer Ther. 2006, 6 (1), 109-120.
2. Marumoto, T.; Zhang, D.; Saya, H. Aurora-A - a guardian of poles. Nat. Rev. Cancer 2005, 5 (1), 42-50.
3. Bischoff, J. R.; Anderson, L.; Zhu, Y.; Mossie, K.; Ng, L.; Souza, B.; Schryver, B.; Flanagan, P.; Clairvoyant, F.; Ginther, C.; Chan, C. S.; Novotny, M.; Slamon, D. J.; Plowman, G. D. A homolog of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 1998, 17 (11), 3052-3065.
4. Warner, S. L.; Bearss, D. J.; Han, H.; Von Hoff, D. D. Targeting Aurora-2 kinase in cancer. Mol. Cancer Ther. 2003, 2 (6), 589-95.
5. Bar-Shira, A.; Pinthus, J. H.; Rozovsky, U.; Goldstein, M.; Sellers, W. R.; Yaron, Y.; Eshhar, Z.; Orr-Urtreger, A. Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. Cancer Res. 2002, 62, 6803-6807.
6. Bischoff, J. R.; Anderson, L.; Zhu, Y.; Mossie, K.; Ng, L.; Souza, B.; Schryver, B.; Flanagam, P.; Clairvoyant, F.; Ginther, C.; Chan, C. S.; Novotny, M.; Slamon, D. J.; Plowman, G. D. A homolog of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 1998, 17, 3052-3065.
7. Wang, X.; Zhou, Y. X.; Qiao, W.; Tominaga, Y.; Ouchi, M.; Ouchi, T.; Deng, C. X. Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 2006, May 22; Epub ahead of print.
8. Harrington, E. A.; Bebbington, D.; Moore, J.; Rasmussen, R. K.; Ajose-Adeogun, A. O.; Nakayama, T.; Graham, J. A.; Demur, C.; Hercend, T.; Diu-Hercend, A.; Su, M.; Golec, J. M. C.; Miller, K. M. X-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. 2004, 10 (3), 262-327.
9. Manfredi, M.; Ecsedy, J.; Meetze, K.; Balani, S.; Burenkova, O.; Chen, W.; Hoar, K.; Huck, J.; Leroy, P.; Sells, T.; Stroud, S.; Vos, T.; Weatherhead, G.; Wysong, D.; Zhang, M.; Claiborne, C. MLN8054, an orally active Aurora A kinase small molecule inhibitor in phase I clinical trials. 97th Annual AACR Meeting, Washington, DC, 2006, Abstract 4724.
10. Wilkinson, R. W.; Keen, N.; Odedra, R.; Heaton, S. P.; Wedge, S. R.; Foote, K. M.; Mortlock, A.; Jung, F.; Heron, N. M.; Brady, M. C.; Walker, M.; Khatri, L.; Barrass, N. C.; Foster, J. J.; Green, S. AZD1152: A highly potent and specific aurora kinase inhibitor. 97th Annual AACR Meeting, Washington, DC, 2006, Abstract 5673.
11. Fancelli, D.; Berta, D.; Bindi, S.; Cameron, A.; Cappella, P.; Carpinelli, P.; Catana, C.; Forte, B.; Giordano, P.; Giorgini, M. L.; Vulpetti, A.; Mantegani, S.; Marsiglio, A.; Meroni, M.; Moll, J.; Pittalà, V.; Roletto, F.; Severino, S.; Soncini, C.; Storici, P.; Tonani, R.; Varasi, M.; Vianello, P. Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J. Med. Chem. 2005, 48 (8), 3080-3084.
12. Soncini, C.; Carpinelli, P.; Gianellini, L.; Fancelli, D.; Vianello, P.; Rusconi, L.; Storici, P.; Zugnoni, P.; Pesenti, E.; Croci, W.; Ceruti, R.; Giorgini, M. L.; Cappella, P.; Ballinari, D.; Sola, F.; Varasi, M.; Bravo, R.; Moll, J. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Clin. Cancer Res. 2006, 12 (13), 4080-4089.
13. Terada, Y.; Tatsuka, M.; Suzuki, F.; Yasuda, Y.; Fujita, S.; Otsu M.; AIM-1: A mammalian midbody-associated protein required for cytokinesis. EMBO J. 1998, 17, 667-676.
14. Ditchfield, C.; Johnson, V. L.; Tighe, A.; Ellston, R.; Haworth, C.; Johnson, T.; Mortlock, A.; Keen, N.; Taylor S. S.; Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell Biol. 2003, 161, 267-280.
15. Jones, R. L.; Judson, I. R. The development and application of imatinib. Exp. Opin. Drug Safety 2005, 4 (2), 183-191.
16. Kouvaraki, M. A.; Shapiro, S. E.; Perrier, N. D.; Cote, G. J.; Gagel, R. F.; Hoff, A. O.; Sherman, S. I.; Lee, J. E.; Evans, D. B. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 2005, 15 (6), 531-544.
17. Greco, A.; Mariani, C.; Miranda, C.; Lupas, A.; Pagliardini, S.; Pomati, M.; Pierotti, M. A. The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol. Cell. Biol. 1995, 5 (11), 6118-6127.
18. George, D. J.; Suzuki, H.; Bova, G. S.; Isaacs, J. T. Mutational analysis of the TrkA gene in prostate cancer. Prostate 1998, 36 (3), 172-180.
19. Pevarello, P.; Brasca, G. M.; Amici, R.; Orsini, P.; Traquandi, G.; Corti, L.; Piutti, C.; Sansonna, P.; Villa, M.; Pierce, B. S.; Pulici, M.; Giordano, P.; Martina, K.; Fritzen, E. L.; Nugent, R. A.; Casale, E.; Cameron, A.; Ciomei, M.; Roletto, F.; Isacchi, A.; Fogliatto, G.; Pesenti, E.; Pastori, W.; Marsiglio, A.; Leach, K. L.; Clare, P. M.; Fiorentini, F.; Varasi, M.; Vulpetti, A.; Warpehoski, M. A. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding. J. Med. Chem. 2004, 47 (13), 3367-3380.
20. Crosio, C.; Fimia, G. M.; Loury, R.; Kimura, M.; Okano, Y.; Zhou, H.; Sen, S.; Allis, C. D.; Sassone-Corsi, P. Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol. Cell. Biol. 2002, 22 (3), 874-885.